Asset profile
Rabeprazol sodium
Unknown / undisclosed
Evidence outlook · lead readout
NCT03143166 · Non-alcoholic Fatty Liver Disease
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT03143166: This was an open-label, single-arm pharmacokinetic study in healthy volunteers, not a randomized or placebo-controlled trial of a disease treatment, and it tested a drug interaction rather than the named drug's own clinical effect.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.